Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076)

Key facts

Sponsor

Genelux Corporation

Principal Investigator

Robert W. Holloway, MD

AdventHealth Cancer Institute

Intervention

olvimulogene nanivacirepvec(biological)

Enrollment

186 enrolled

Eligibility

18 years · FEMALE

Timeline

2022 – 2026

Study locations (30)

• The University of South Alabama, Mitchell Cancer Institute, Mobile, Alabama, United States
• University of Arizona Cancer Center, Tucson, Arizona, United States
• City of Hope, Duarte, California, United States
• UC San Diego Health - Moores Cancer Center, La Jolla, California, United States
• Hoag Gynecologic Oncology, Newport Beach, California, United States
• UCI Health Chao Family Comprehensive Cancer Center, Orange, California, United States
• AdventHealth Cancer Institute, Orlando, Florida, United States
• Sarasota Memorial Research Institute, Sarasota, Florida, United States
• Emory University, Atlanta, Georgia, United States
• Indiana University Simon Comprehensive Cancer Center, Indianapolis, Indiana, United States
• Holy Cross Hospital, Silver Spring, Maryland, United States
• University of Michigan, Ann Arbor, Michigan, United States
• Karmanos Cancer Institute, Detroit, Michigan, United States
• Washington University School of Medicine, St Louis, Missouri, United States
• Mercy Hospital St. Louis, St Louis, Missouri, United States
• +15 more locations on ClinicalTrials.gov

Collaborators

GOG Foundation

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for OBSOLETE: Primary peritoneal serous/papillary carcinoma

Additional recruiting or active studies for the same condition.

• RECRUITINGPHASE1NCT06856499
  Cirtuvivint/Olaparib in Breast Cancer Susceptibility Gene/Homologous Recombination Deficiency Platinum Resistant Ovarian Cancer
  University of Colorado, Denver
• RECRUITINGPHASE3NCT06994195
  A Study Comparing BL-B01D1 With the Investigator's Choice of Chemotherapy in Patients With Platinum-resistant Recurrent Epithelial Ovarian Cancer
  Sichuan Baili Pharmaceutical Co., Ltd.
• RECRUITINGPHASE2NCT07024784
  A Study to Assess Change in Disease Activity and Adverse Events in Adult Participants With Gynecologic Cancers Receiving Intravenous Infusion of IMGN151 as Monotherapy or in Combination With Other Therapies
  AbbVie
• RECRUITINGNANCT06969833
  Prospective Clinico-biological Database of Patients With Ovarian and/or Peritoneal and/or Fallopian Tube Carcinoma
  Centre Oscar Lambret
• RECRUITINGPHASE3NCT05659381
  Heated Intraperitoneal Chemotherapy Followed by Niraparib for Ovarian, Primary Peritoneal and Fallopian Tube Cancer
  GOG Foundation
• RECRUITINGNANCT05597683
  Quadratus Lumborum Block After Cytoreductive Surgery and Hyperthermic Intra-peritoneal Chemotherapy
  Gangnam Severance Hospital
• ACTIVE NOT RECRUITINGPHASE2NCT05456685
  Mirvetuximab Soravtansine (MIRV) With Carboplatin in Second-line Treatment of Folate Receptor Alpha (FRα) Expressing, Platinum-sensitive Epithelial Ovarian Cancer
  AbbVie
• ACTIVE NOT RECRUITINGPHASE2NCT05406674
  Body Surface Area-based vs Concentration-based Dosing of Cisplatin for Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Women With Advanced Ovarian Cancer
  The Netherlands Cancer Institute

See all trials for OBSOLETE: Primary peritoneal serous/papillary carcinoma →